Accueil   Diary - News   All news Valneva and HOOKIPA Sign a Collaboration and Manufacturing Agreement

Valneva and HOOKIPA Sign a Collaboration and Manufacturing Agreement

 

Saint-Herblain, France, and Vienna, Austria, December 06, 2018 – Valneva Sweden AB, the Swedish subsidiary of Valneva SE (“Valneva”), and HOOKIPA Pharma Inc. (“HOOKIPA”) today announced that they have entered into a three-year collaboration and manufacturing agreement.

 

Under the terms of the agreement, Valneva Sweden will provide analytical services, develop process scale-up and produce GMP clinical trial material to support the development of new immunotherapies based on HOOKIPA’s Vaxwave®*and TheraT®*arenavirus vector- technologies. In return, Valneva will receive fixed and success-based service fees. The agreement may be extended beyond three years.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree